Engene holdings inc.ENGN.US Overview

US StockHealthcare

(No presentation for ENGN)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ENGN Overall Performance

ENGN AI Analysis & Strategy

ENGN Recent Performance

4.68%

Engene holdings inc.

1.30%

Avg of Sector

0.61%

S&P500

ENGN PowerScanner

ENGN Key Information

ENGN Valuation Metrics

ENGN Earnings Table

ENGN Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.